跳到主要內容

Coulter James G 的 Form 4 申報

Odyssey Therapeutics, Inc.ODTX,2026/5/13 申報

申報編號
0001999371-26-010652
申報時間
2026/5/13 17:10 ET
交易日
2026/5/11
申報延遲
2 天
10b5-1 計畫
沒有勾選

這份申報列了 4 筆非衍生性交易、2 筆衍生性交易。公開市場買進合計 $2,500 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Coulter James GCIK 0001099776其他:Former 10% Owner
Winkelried JonCIK 0001366946其他:Former 10% Owner
TPG GP A, LLCCIK 0001903793其他:Former 10% Owner

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2026/5/11Common StockJ其他取得+423,111–F3–423,111間接
2026/5/11Common StockJ其他處分−2,351$18.00F3−$42,318420,760間接
2026/5/11Common StockC轉換取得+1,880,497–F4–2,301,257間接
2026/5/11Common StockP買進取得+1,388,889$18.00+$25,000,0023,690,146間接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2026/5/11Common StockJ其他處分−423,111–F3–0間接
2026/5/11Common StockC轉換處分−1,880,497–F4–0間接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F3

The Warrants to Purchase Common Stock (the "Warrants") directly held by TPG Orazio I were, pursuant to their terms, deemed automatically exercised, by way of a cashless net issue exercise, for shares of Common Stock upon consummation of the Issuer's initial public offering on May 11, 2026. Each Warrant had been exercisable for one share of Common Stock at an exercise price of $0.10 until the earlier of (i) June 16, 2032 and (ii) a "Corporate Transaction" (defined as the consummation of a Deemed Liquidation Event (as defined in the Issuer's Certificate of Incorporation (as defined below)) and the closing of the Issuer's initial public offering).

表 I 有 2 筆、表 II 有 1 筆交易的價格引用這則附註。

F4

Pursuant to the Eighth Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") of the Issuer, as amended, the shares of Series D Preferred Stock of the Issuer (the "Preferred Stock") directly held by TPG Orazio I automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering on May 11, 2026 at a conversion rate (as adjusted for a reverse stock split) equal to one share of Common Stock per 9.7170 shares of Preferred Stock. The shares of Preferred Stock had previously been convertible, at the option of the holder, at any time into shares of Common Stock.

表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。

備註

(8) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (9) Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)